TransMedics Group, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US89377M1099
USD
138.63
-3.14 (-2.21%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About TransMedics Group, Inc. stock-summary
stock-summary
TransMedics Group, Inc.
Pharmaceuticals & Biotechnology
Transmedics group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Lung INSPIRE Trial, OCS Lung Expand Trial, OCs Heart EXPAND and PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. It is also focused on developing additional OCS products for kidney transplantation.
Company Coordinates stock-summary
Company Details
84 State St , BOSTON MA : 02109-2202
stock-summary
Tel: 1 978 5520900
stock-summary
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 103 Schemes (71.76%)

Foreign Institutions

Held by 161 Foreign Institutions (31.59%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. James Tobin
Independent Chairman of the Board
Dr. Waleed Hassanein
President, Chief Executive Officer, Director
Ms. Merilee Raines
Director
Mr. Edward Basile
Independent Director
Mr. Thomas Gunderson
Independent Director
Mr. Edwin Kania
Independent Director
Dr. David Weill
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
157 Million
(Quarterly Results - Jun 2025)
Net Profit:
35 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,599 Million (Small Cap)

stock-summary
P/E

96.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.36

stock-summary
Return on Equity

22.53%

stock-summary
Price to Book

11.31